Summary Haplogen GmbH (Haplogen) is a biopharmaceutical company that improves human health by fighting against infectious diseases such as common cold, dengue fever, influenza and hepatitis C.The company utilizes its proprietary genetics technology platform to identify novel pathogen host factors and develops therapeutics for the treatment of infectious diseases.
It undertakes the construction of next generation haploid genetics tools to support experimental human genetics and internal target discovery programs.Haplogen works in partnership with pharmaceutical and biotechnology companies to advance its drug discovery and development pipeline.
The company collaborates with professional experts and partners. Haplogen is headquartered in Vienna, Austria.
Haplogen GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
In terms of value, the sterile medical packaging market size is estimated to be USD 36.9 billion in 2020 and projected to reach USD 57.7 billion by 2025, at a CAGR of 9.4% from 2020 to 2025. Increasing investment, coupled with growth in healthcare industry across the globe is expected to drive the growth of sterile medical packaging market....
Electrophysiology Devices - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Electrophysiology Devices - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Electrophysiology Devices pipeline products with comparative analysis of...
Acromegaly - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape. Acromegaly is a hormonal disorder that develops when pituitary...
Mechanical Circulatory Support Devices - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Mechanical Circulatory Support Devices - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Mechanical Circulatory Support Devices pipeline...
The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020–2027. The growth of the late stage chronic kidney disease drugs market is mainly attributed to the factors such as high prevalence...
The clinical trial supplies market was valued at US$ 1,867.44 million in 2019 and is expected to grow at a CAGR of 7.4% from 2020 to 2027 to reach US$ 3,298.91 million by 2027. Driving factors of the clinical trial supplies market are increasing pharmaceutical and biopharmaceutical R&D expenditures and an increase in several clinical...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.